The Food and Drug Administration has added new data for TUDORZA® PRESSAIR®, a medication to treat chronic obstructive pulmonary disease. The medication reduces exacerbations in COPD and does not increase major adverse cardiovascular events in patients with cardiovascular disease and/or significant cardiovascular risk factors
ASCENT was a randomized, double-blind, placebo-controlled three year study that evaluated the effect of the medication on patients with moderate-to-severe COPD and whether they had major adverse cardiovascular events.
The recent trial showed that the medication’s use led to consistent reduction in exacerbations and reductions in flare-ups. This leads to fewer emergency room visits and hospital admissions, according to Kenneth Chapman, M.D., Clinical Researcher at the Krembil Research Institute, University Health Network at theUniversity of Toronto, and an investigator on the ASCENT trial.
“The expanded label for TUDORZA PRESSAIR is welcome news for the COPD community and providers who care for COPD patients,” said David Acheson, Senior Vice President, US Commercial, Circassia. “Circassia is proud to be a leader in the respiratory health space, and today’s news further demonstrates our commitment to respiratory health.”
